Tailai Biosciences Debuts Multi-Omics Liquid Biopsy Platform AnAnPan™ at Suzhou AI Expo

VCBeat (WeChat ID: biobeat1) has learned that the “M-TECH 2019 Smart Healthcare Innovation Industry Forum” was recently held successfully in Suzhou. This forum served as the healthcare industry sub-venue of the 2019 Global AI Product Application Expo. It was organized by Maike Network, with co-organization by Heli Investment, SIPAI, and Dandelion Incubator. The event brought together leading experts from the forefront of the healthcare and artificial intelligence industries to share the latest advancements in AI-enabled smart healthcare across areas such as early cancer screening, single-cell sequencing, personalized tumor vaccines, human microbiome, and medical imaging. Participants engaged in multi-dimensional discussions on the prospects and possibilities for translating smart healthcare innovations from scientific research into commercial applications.

TaiLai Biosciences, a company specializing in cancer screening, was invited to attend this forum, where it presented its proprietary multi-omics technology and provided a brief introduction to its upcoming first early cancer screening product, AnAnPan™ (Meta-Pan™).

TaiLai Biosciences is a biotechnology company jointly established by a seasoned medical industry team and a cutting-edge scientific team, offering next-generation biopsy products and services based on proprietary multi-omics technologies. Multi-omics technology represents a novel biological analytical approach that leverages large-scale molecular-level biological data across multiple dimensions of life processes—including the genome, transcriptome, epigenome, proteome, metabolome, and microbiome. By employing bioinformatics statistical analysis, computational biology, and machine learning, this technology enables high-level analysis and interpretation of complex biological phenomena involving numerous factors, such as life processes and diseases. In addition to cancer screening, it facilitates comprehensive research into the relationship between human genetic diversity and health.

At the forum, Dr. Zhong Sheng, Vice President of Research and Development at TaiLai Biosciences, stated: “Multi-omics technologies are highly interdisciplinary and complex in nature. Therefore, our team brings together experts from cutting-edge fields such as biochemistry, molecular biology, biomaterials engineering, and computational science. In addition, Professor Wang Yunbing, a leading expert in biomaterials in China, and Professor Michael Snyder from Stanford University, a pioneering scientist in international multi-omics, serve as key members of our Scientific Advisory Board.”

Dr. Sheng Zhong, Vice President of Biomedical Research and Development at TaiLai Biosciences

It is reported that TaiLai Biosciences maintains close scientific research collaborations with the National Engineering Research Center for Biomaterials, Zhongshan Hospital Affiliated to Fudan University, and Stanford University in the United States. To date, the company has jointly developed multiple liquid biopsy technologies based on metabolomics and epigenetics, and possesses extensive reserves of analytical technologies based on genomics, transcriptomics, microbiomics, and medical imaging.

Dr. Zhang Hua, an Associate Research Fellow at the National Engineering Research Center for Biomaterials and a core team member of TaiLai Biosciences, stated at the forum: “The application of multi-omics technology has ushered in a new era for cancer screening. TaiLai Biosciences’ latest innovation, AnAnPan™ (Meta-Pan™), represents the translational application of metabolomics research findings to the field of early cancer screening. Through the development of proprietary biomaterials and the upgrading of specific algorithms and analytical computational methods, we are able to capture trace amounts of metabolic markers. This significantly advances the stage at which tumors can be detected and enhances the accuracy of screening.”

Dr. Zhang Hua, Associate Research Fellow at the National Engineering Research Center for Biomaterials

As a pioneer in next-generation liquid biopsy, TaiLai Biosciences has launched AnAnPan™ (Meta-Pan™), which covers more than ten types of cancer with the highest incidence and mortality rates in China. Based on clinical study results from over 10,000 samples, the test demonstrates a specificity exceeding 98% for all detected cancer types, with sensitivity greater than 92% for the vast majority of these cancers.

Promoting early diagnosis and treatment of cancer, and identifying approaches that are suited to China’s national conditions and easily scalable for widespread adoption in large populations, has become a consensus priority for scientific and technological breakthroughs in this field. For example, Prevention Oncology, edited by Zhao Ping, Chairman of the China Cancer Foundation, and others, cites that screening with spiral CT can reduce lung cancer mortality; however, its high cost hinders broad population-level implementation. AnAnPan™ (Meta-Pan™) provides non-invasive, pan-cancer risk assessment for individuals, while its laboratory sample processing features high throughput and semi-automated handling, thereby overcoming longstanding challenges in the in vitro screening industry.

Following the conference, Dr. Zhong Sheng revealed that the scientific team at TaiLai Biosciences continues to expand the range of cancers covered by AnAnPan™ (Meta-Pan™), while deeply advancing research in multi-omics technologies. The company aims to provide a diverse portfolio of auxiliary and companion diagnostic products for various diseases and disease stages. Through the evolution and application of new technologies, TaiLai Biosciences seeks to drive continuous breakthroughs toward intelligent industrial innovation in China’s fields of early cancer screening and precision medicine.

TaiLai Biosciences was co-founded by a seasoned medical industry team and a cutting-edge scientific team comprising top-tier experts, professors, PhDs, and scientists in the field. It is a biotechnology company that provides next-generation biopsy products and services based on proprietary multi-omics technologies.

TaiLai Biosciences adheres to the philosophy that “prevention is better than cure.” Deeply engaged in the research, development, and translation of multi-omics and liquid biopsy technologies, the company offers a suite of precise disease screening services. These solutions help the general public detect health risks earlier for effective prevention, or enable early clinical intervention by physicians, significantly reducing treatment complexity and improving survival rates.

TaiLai Biosciences looks forward to turning more cutting-edge technologies into reality, providing precise diagnosis and treatment solutions for a wider range of human diseases.